胺三甲衍生物作为人类二叶酸减少酶抑制剂-分子建模和体外活性研究
Danuta Drozdowska1, Agnieszka Wróbel-Tałałaj1, Cezary Parzych2
1Department of Organic Chemistry, Medical University of Białystok, Mickiewicza Street 2A, 15-222 Białystok, Poland.
Biomedicines
|May 25, 2024
概括
新的胺衍生物显示出人类二叶酸减少酶 (hDHFR) 的强烈抑制,这是癌症治疗的关键标. 化合物JW2和JW8表现出有前途的活性和酶稳定性,这表明它们有可能成为新型治疗药物.
科学领域:
- 药用化学 医学化学
- 酶抑制可以抑制酶.
- 药物发现 药物发现 药物发现
背景情况:
- 人类二叶酸减少酶 (hDHFR) 是细胞功能的关键酶,也是癌症化疗的验证标.
- 三甲 (TMP) 是一种已知的hDHFR抑制剂,作为开发新治疗剂的基准.
- 在TMP类似物中加入一种由DNA小沟结合剂 (如网素) 启发的胺键,是发现新抑制剂的新策略.
研究的目的:
- 合成和评估一系列新的胺衍生物作为人类二叶酸减少酶 (hDHFR) 的潜在抑制剂.
- 评估这些化合物对乙胆酶 (AChE) 和β-分泌酶 (BACE1) 作为次要标的抑制活性.
- 研究最有前途的化合物对hDHFR酶的分子相互作用和稳定作用.
主要方法:
- 11种胺衍生物 (JW1-JW8,MB1,MB3,MB4) 的合成和表征.
- 在体外酶分析以确定对hDHFR,ACHE和BACE1.1的抑制度 (IC50).
- 分子建模研究以阐明与hDHFR的结合相互作用,包括关键残留物和结合模式.
主要成果:
- 所有合成的胺胺都对hDHFR表现出显著的活性,IC50值在4.72至20.17μM之间,优于参考TMP (55.26μM).
- 化合物JW8对AChE (IC50 = 0.056μM) 和BACE1 (IC50 = 9.01μM) 呈现强烈的抑制作用.
- 衍生品JW2和JW8被确定为最有前途的hDHFR抑制剂,与关键残留物 (JW2的Gly-117;JW8的Asn-64和Arg-70) 显示强烈的相互作用,并稳定了酶.
结论:
- 新型胺衍生物代表了一类有前途的化合物,具有药用化学应用的重大潜力.
- 化合物JW2和JW8特别值得注意的是它们对酶的强烈hDHFR抑制和稳定作用.
- 这项研究验证了将胺键纳入TMP类型的策略,用于开发具有潜在抗癌活性的新型hDHFR抑制剂.
相关概念视频
Antihypertensive Drugs: Thiazide-Class Diuretics
604
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
604
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Phase I Reactions: Reductive Reactions
199
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
199
Amines to Sulfonamides: The Hinsberg Test
3.4K
The Hinsberg test is a method to identify primary, secondary and tertiary amines, named after its pioneer, Oscar Hinsberg. Here, amines are treated with benzenesulfonyl chloride, also known as the Hinsberg reagent, in the presence of an excess of aqueous base, followed by acidification. Based on the nature of the amines, different changes are observed.
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing...
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing...
3.4K
Phase II Reactions: Methylation Reactions
178
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
178


